ArticleMolecular genetics & genomic medicine2026
ABCA4-Associated Retinal Degeneration in 8 Families From the Three Provinces of Northeast China: Identification and Characterization of Potentially Novel Variants.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study characterizes the clinical and genetic features of ABCA4-associated inherited retinal diseases (IRDs) in eight unrelated probands from the three provinces of Northeast China. All patients harbored biallelic pathogenic ABCA4 variants, with detailed variant profiles provided in Table 2.
methodsEight unrelated Chinese pedigrees (31 individuals, including 8 probands and 23 family members) with ABCA4-related IRDs. All participants underwent comprehensive ophthalmic examinations. Genetic variants were identified using a targeted next-generation sequencing (NGS) panel for IRDs. For all candidate pathogenic variants, in silico pathogenicity predictions were performed using REVEL, PolyPhen-2, MutationTaster, SIFT, and LRT (Likelihood Ratio Test). The pathogenicity of the variants was classified in accordance with the guidelines of the American College of Medical Genetics and Genomics (ACMG), integrating computational evidence and segregation analysis. All candidate variants were validated by bidirectional Sanger sequencing, and co-segregation analysis was performed in available family members.
resultsSixteen ABCA4 variants were identified, including six novel potentially deleterious variants (three predicted loss-of-function). ACMG classifications comprised six pathogenic variants, eight likely pathogenic variants, and two variants of uncertain significance (VUS). Phenotypically, six probands presented with Stargardt disease type 1 (STGD1), one with early-onset severe retinal dystrophy (EOSRD, compound heterozygous ABCA4 variants), and one with an unclassified IRD. The three provinces of Northeast China STGD1 patients displayed a higher proportion of mild-severity variants yet presented with an earlier median onset age (10.6 years) and more severe visual impairment (77.2% with best-corrected visual acuity < 0.1) when compared to global cohorts. However, this observation may reflect referral bias to a tertiary center and requires validation in larger, multi-ethnic cohorts.
conclusionsTargeted NGS identified six potentially novel ABCA4 variants in the Northeast Chinese population, including three predicted loss-of-function variants. This study reports a case of ABCA4 associated EOSRD, thereby broadening the documented ABCA4 variant spectrum in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.